GlassScriptPhysician profile
Lazaro U Rabang
NPI 1649387697
$16,577.61
in general payments reported to CMS, 2019-2025
43 companies · $2,995 in 2025
The $2,995 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $1,076 · 2021: $3,066 · 2022: $2,428 · 2023: $2,122 · 2024: $2,696 · 2025: $2,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,794 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,794.02 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,780.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,554.94 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,434.13 | 2019-2023 | |
| Abbvie INC. | $1,345.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,230.77 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,196.70 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $937.05 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $836.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $830.33 | 2019-2021 | |
| Abbott Laboratories | $589.28 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $572.09 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $541.78 | 2019-2024 | Veozah |
| Lilly USA, LLC | $396.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $349.02 | 2020-2024 | Capvaxive, Gardasil 9, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.37 | 2021-2025 | Xifaxan, Trulance |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $285.60 | 2019-2025 | Austedo Xr |
| Mylan Specialty L.P. | $265.38 | 2020-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $254.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.49 | 2020-2025 | Trintellix |
| Actelion Pharmaceuticals US, INC. | $200.41 | 2023-2025 | Opsumit, Uptravi |
| Biohaven Pharmaceuticals, INC. | $181.72 | 2021 | |
| Sunovion Pharmaceuticals INC. | $170.70 | 2019-2022 | |
| Lundbeck LLC | $149.34 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $114.28 | 2023 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.99 | 2025 | Caplyta |
| Lexicon Pharmaceuticals, INC. | $80.69 | 2024 | Inpefa |
| Allergan, INC. | $75.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $74.23 | 2023-2025 | Shingrix |
| Idorsia Pharmaceuticals US INC | $70.51 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $68.24 | 2020-2025 | |
| Almatica Pharma LLC | $56.56 | 2023-2025 | Loreev Xr |
| Viatris Specialty LLC | $49.70 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $39.86 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $33.28 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $32.00 | 2025 | Inspire |
| Dexcom, INC. | $30.51 | 2022-2023 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $19.14 | 2024 | Prolastin-C Liquid |
| Amgen INC. | $18.95 | 2020 | |
| Insulet Corporation | $18.89 | 2024 | Omnipod |
| Genentech USA, INC. | $17.99 | 2020 | |
| Convatec INC. | $17.07 | 2024 | |
| Seqirus USA INC | $15.67 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lazaro Rabang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.